Cognetivity Neurosciences Ltd. CGNSF

Company Overview

Cognetivity Neurosciences Ltd. (OTCQB: CGNSF) is a Canadian technology and medical diagnostics company focused on developing cognitive assessment tools that use artificial intelligence and machine learning to assist in the early detection of cognitive impairment and neurological conditions. The company operates at the intersection of digital health, neuroscience, and medical technology, with a primary emphasis on computerized cognitive testing platforms intended for use in healthcare and clinical environments. Its principal product platform is the Integrated Cognitive Assessment (ICA), a rapid computerized assessment designed to evaluate cognitive performance without relying heavily on language, education level, or cultural background.

The company’s core revenue strategy has centered on commercialization of its cognitive assessment technology through healthcare providers, research institutions, and potential licensing arrangements. Cognetivity has positioned itself as a developer of scalable, non-invasive digital diagnostics that may support earlier identification of conditions such as dementia, mild cognitive impairment, and other neurological disorders. The company was founded in 2017 and has evolved from a neuroscience-focused technology startup into a publicly traded medical technology company pursuing regulatory approvals, commercial partnerships, and broader international adoption of its cognitive testing platform.